Share this Page:
In a study reported in the August issue of the European Journal of Cancer, a group of American investigators reported findings from patients with melanoma, renal cell carcinoma (RCC) and non-small cell lung cancer (NSCLC) who survived longer than two years after treatment with PD-1 and PD-L1 inhibitors (immune checkpoint inhibitors).
In conclusion, most patients who survive more than 24 months after treatment with immune checkpoint inhibitors had durable benefit and favourable HRQoL outcomes. Chronic immune-related adverse events may be more common than previously thought. However, there were no long-term adverse cardiometabolic events (a combination of high blood pressure, high glucose levels, high levels of fats in the blood, and accumulation of fat in the tummy).
